Clinical and biological heterogeneity of autoimmune myasthenia gravis

Research output: Contribution to journalArticle

22 Citations (Scopus)


Although myasthenia gravis (MG) has long been considered a well-established autoimmune disease associated with autoantibodies, which are convincingly pathogenic, accumulating data indicate both clinical and biological heterogeneity similar to many other putative autoimmune disorders. In a subset of patients, thymus plays a definite role: thymic autoimmunity results in generation of autoantibodies within the thymus, which cross-react with antigens at the neuromuscular junction, or thymoma leads to deficient central tolerance and impaired T cell selection. Heterogeneity on the autoantibody level may be associated with genetic heterogeneity and clinical phenotypes with different treatment responses.

Original languageEnglish
Pages (from-to)43-54
Number of pages12
JournalJournal of Neuroimmunology
Issue number1-2
Publication statusPublished - Feb 1 2011



  • Acethylcholine receptor
  • Acetylcholine
  • Antibodies
  • MuSK
  • Neuromuscular junction
  • Thymoma
  • Thymus

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Cite this